Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Sun Pharma Licenses Merck Psoriasis Drug for $80M

September 17, 2014 3:02 pm | News | Comments

Merck is licensing an experimental psoriasis drug to Indian drugmaker Sun Pharmaceuticals, the companies said Wednesday. Sun will pay Merck $80 million upfront and will gain the right to market the drug, called tildrakizumab. Read more...    

TOPICS:

1st Volunteer Gets Experimental Ebola Vaccine

September 17, 2014 12:46 pm | News | Comments

British scientists say a former nurse has become the first person in the country to receive an experimental Ebola vaccine in an early trial to test its safety. Read more...                       

TOPICS:

Sanofi Enters Groundbreaking Heart Disease Collaboration with MyoKardia

September 17, 2014 10:57 am | News | Comments

Sanofi and MyoKardia Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. Read more...   

TOPICS:
Advertisement

EMD Serono, Sutro Biopharma Partner on ADCs

September 17, 2014 10:52 am | News | Comments

EMD Serono Inc., a subsidiary of Merck KGaA, and Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). Read more...

TOPICS:

Merck Diabetes Drug Hits Endpoints in Japanese Study

September 17, 2014 10:44 am | News | Comments

Merck announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. Read more...         

TOPICS:

Glenmark's TRPA1 Antagonist Excels in Phase 2a

September 17, 2014 10:33 am | News | Comments

Glenmark Pharmaceuticals announced that its first-in-class Transient Receptor Potential Ankyrin 1 antagonist, GRC 17536, has shown positive data in a Phase 2a study conducted on 138 patients in Europe and India. Read more...       

TOPICS:

Auxilium Adopts 'Poison Pill' Plan After $1.41B Offer from Endo

September 17, 2014 10:21 am | News | Comments

The board of Auxilium Pharmaceuticals Inc. has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker. Read more...

TOPICS:

Australia Promises $6.4M to Fight Ebola

September 17, 2014 10:17 am | News | Comments

Australia announced on Wednesday it will immediately provide an additional 7 million Australian dollars ($6.4 million) to help the international response to the Ebola outbreak in West Africa. Read more...              

TOPICS:
Advertisement

Relmada in MOA Agreement With MSKCC

September 16, 2014 3:47 pm | News | Comments

Relmada Therapeutics Inc. announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of LevoCap ER. Read more...         

TOPICS:

TapImmune Releases Interim Data on Phase 1 Cancer Trial

September 16, 2014 3:39 pm | News | Comments

TapImmune Inc. reported that analysis of the interim data from the first 13 patients in a Phase 1 clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of five naturally processed folate receptor alpha Class II antigenic epitopes. Read more...

TOPICS:

Amarin Committed to Completing Cardiovascular Outcomes Study

September 16, 2014 3:34 pm | News | Comments

Amarin Corp. announced its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial) cardiovascular outcomes study. Read more...                 

TOPICS:

Mylan to Begin Phase 3 Trials on Key Generics

September 16, 2014 3:28 pm | News | Comments

Mylan Inc. announced it is initiating Phase 3 clinical trials for its generic version of GlaxoSmithKline's Advair Diskus and its insulin analog to Sanofi's Lantus.  Read more...                   

TOPICS:

Nektar Says FDA Clears Constipation Drug Movantik

September 16, 2014 2:41 pm | News | Comments

Nektar Therapeutics said Tuesday that U.S. regulators approved its drug Movantik, a once-per-day treatment for constipation caused by opioid painkillers. Movantik, or naloxegol, is approved for adults who have chronic pain that is not caused by cancer. Read more...

TOPICS:

Lilly, AstraZeneca Team Up on Alzheimer's Drug

September 16, 2014 11:43 am | News | Comments

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing. Read more...      

TOPICS:

Bayer, Orion Initiate Phase 3 Prostate Cancer Trial

September 16, 2014 10:26 am | News | Comments

Bayer HealthCare and Orion Corp. have begun to enroll patients in a Phase 3 trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment of patients with prostate cancer. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading